Nykode Therapeutics ASA (NYKD) fair value: what the stock is really worth
As of Nov 19, 2026: fair value (intrinsic value) of Nykode Therapeutics ASA stock NOK 2.45, price NOK 2.74, that is 10.4% below the price, quality 67 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Nykode Therapeutics ASA
NYKD · OLExpensive (fair value 10% below the price), but solid company and rising price: meets 2 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range kr 1.27 – kr 54.35 · fair‑value band kr 1.84 – kr 3.07 · the kr 2.74 price screens above the kr 2.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Nykode Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases.
Show moreShow less
Its lead product candidates include ABI-SUVA for targeting HPV16+ induced malignancies, with head, and neck cancer as the primary indication is in Phase 2 randomized controlled trial.
It also offers VB10.NEO, which is in Phase1b VB-N-02 trial; technology platform, which combines genes with desired properties to make novel compounds by creating a new code. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Stock analysis
Nykode Therapeutics ASA (NYKD) currently trades at kr 2.74, while our estimate is kr 2.45, 10% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: kr 1.84 (bear) to kr 3.07 (bull), the price of kr 2.74 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Nykode Therapeutics ASA reported revenue of $0 in FY2025 versus $34.0M in FY2021. Reported net income was −$12.2M in FY2025.
Key figures
Market cap 1.1B NOK (≈ $112M) Micro · EPS (TTM) kr −0.5900 · Dividend yield 2.7% · Return on equity −25.1% · Return on assets (EBIT) −23.2% (5-year average) · Operating margin −6,363% · Revenue (TTM) 464K NOK · Revenue growth (YoY) −46.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −10%, NYKD screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Nykode Therapeutics ASA with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- Stock screener with 62 metrics
- Valuation of the Norway market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $945.53 | $1,275 | +35% | vs NYKD |
| Vertex Pharmaceuticals Incorporated VRTX | $536.45 | $587.62 | +10% | vs NYKD |
| Samsung Biologics Co 207940 | 1,375,000 KRW | 1,502,600 KRW | +9% | vs NYKD |
| argenx SE ARGX | $941.25 | $908.40 | −3% | vs NYKD |
| CSL Limited CSL | A$199.85 | A$186.49 | −7% | vs NYKD |
| Moderna, Inc MRNA | $196.79 | $135.64 | −31% | vs NYKD |
| BeOne Medicines AG 6160 | HK$242.60 | HK$152.92 | −37% | vs NYKD |
| Revolution Medicines, Inc RVMD | $159.82 | $83.12 | −48% | vs NYKD |
| Celltrion, Inc 068270 | 215,000 KRW | 74,945 KRW | −65% | vs NYKD |
| Royalty Pharma plc RPRX | $68.67 | $19.01 | −72% | vs NYKD |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Nykode Therapeutics ASA (NYKD) overvalued or undervalued?
What is the fair value of NYKD?
What is the quality score of NYKD?
What is the price target for Nykode Therapeutics ASA (NYKD)?
What is the Nykode Therapeutics ASA stock forecast for 2026?
What is the revenue of Nykode Therapeutics ASA (NYKD)?
Does Nykode Therapeutics ASA pay a dividend?
How much is the dividend of Nykode Therapeutics ASA (NYKD)?
What is the intrinsic value of Nykode Therapeutics ASA (NYKD)?
Is Nykode Therapeutics ASA stock overvalued or undervalued in 2026?
Is fair value the same as the market price of NYKD?
How much is Nykode Therapeutics ASA worth?
What do the bullish and bearish scenarios say about NYKD?
How solid is the balance sheet of Nykode Therapeutics ASA (NYKD)?
How far is NYKD from its 52-week high?
Which stocks are comparable to Nykode Therapeutics ASA?
Is Nykode Therapeutics ASA stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Nykode Therapeutics ASA (NYKD)?
What should I pay attention to with Nykode Therapeutics ASA right now?
Key figures of Nykode Therapeutics ASA
How large is the market capitalisation of Nykode Therapeutics ASA (NYKD)?
What are the earnings per share of Nykode Therapeutics ASA (NYKD)?
What is the dividend yield of Nykode Therapeutics ASA (NYKD)?
What is the return on equity of Nykode Therapeutics ASA (NYKD)?
What is the EBIT return on assets of Nykode Therapeutics ASA (NYKD)?
What is the operating margin of Nykode Therapeutics ASA (NYKD)?
How fast is revenue growing at Nykode Therapeutics ASA (NYKD)?
How fast are earnings growing at Nykode Therapeutics ASA (NYKD)?
How much free cash flow does Nykode Therapeutics ASA (NYKD) generate?
How much net cash does Nykode Therapeutics ASA (NYKD) hold?
Watch Nykode Therapeutics ASA in the live analysis
One click puts Nykode Therapeutics ASA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.